(Course of complications)
Early - prognostic - detection of the development of complications of COVID-19 by the DiaPat® CoV-50 test allows the timely application of drugs and prevents intensive medical treatment and the use of ventilators - saves lives and eliminates the need for lockdown measures!
Once a Covid-19 disease has been identified, it can be determined whether the patient has a
- light (WHO grade 1-3 - no inpatient stays, no ventilation requirement)
- severe (WHO grade 4-5 - inpatient surveillance, no intensive care measures yet)
- very severe (WHO grade 6 - intensive care measures, mechanical ventilation if necessary)
development of the disease and can thus receive various therapeutic agents in a good time to prevent severe courses and thus save lives.
First partial result of the ongoing study commissioned by the Ministry of Health
The targeted diagnosis of the prognosis of the Covid-19 disease using the proteome analysis test "CoV-50" (scientifically precise: "COVID50" - 50 individual peptides that form the pattern) has an accuracy is over 90 percent.
The study is open and patients can register to participate.
The design of the study envisages the inclusion of a total of 1,000 patients with three urine samples: 0-2 days, 4-7 and 10-14 days after Covid-19 diagnosis.
Initially, 250 patients (the other 750 patient samples are blinded) were earmarked for validation of the disease-specific proteome pattern. The results will be published shortly and shows over 90 percent accurate detection of the disease development in the first samples after 0-2 days.
The test is not yet available on an outpatient basis. DiaPat® is trying to obtain special approval from the BfArM and the EU Commission for the other EU member states.
All studies to date show the benefits of therapeutic use in the early phase of Covid-19. Only then the individualized dosage and coordination of the different medicinal effects possible efficiently.
This results from the mechanism of action of the drugs:
either: Reduction of the viral load
or: Reduction of the excessive immune reaction
Once organ damage has occurred due to uncontrolled Covid-19 disease, it can no longer be "repaired". The therapy would come too late. If previous damage by the endothelium in the organ vessels is not recognized and therefore not taken into account due to chronic cardiovascular and renal diseases, the prognosis of the Covid-19 course is all the more urgent.
An overview of the individual therapeutic effects and limitations
Remdesivir and in particular antibodies against SARS-CoV-2 are only available to a limited extent and have considerable side effects. Prophylactically, these therapeutics cannot be administered to all patients with Covid-19. Antibodies, in particular, are effective, but rarely available therapeutics.
Steroids are effective in the early stages but have significant side effects. The compromise of the immune system also favors secondary infections, which is why steroids may only be used in a targeted manner.